Bracco Diagnostics Inc. Release: The Latest Head-To-Head Clinical Study Comparing The Risk Of CIN between Two Contrast Agents Used In CE-MDCT Examinations Was Published In Investigative Radiology

PRINCETON, N.J.--(BUSINESS WIRE)--The results of a clinical study comparing Isovue®-370 (iopamidol injection), marketed by Bracco Diagnostics Inc. in the United States, and Visipaque™-320 (iodixanol injection), marketed by GE Healthcare in the United States, in renally Impaired Patients undergoing Computed Tomography (IMPACT) showed no significant difference in the rate of contrast-induced nephropathy (CIN) between the two agents.